

1 **Title: Predictive factors for the development of peritumoral brain edema after LINAC-**
2 **based radiation treatment in patients with intracranial meningioma**

3

4 **Short title:** Peritumoral brain edema after radiation

5

6 **Authors:** Ryang-Hun Lee¹, Jae Min Kim¹, Jin Hwan Cheong¹, Je Il Ryu¹, Young Soo Kim²,
7 Myung-Hoon Han^{1*}

8

9 ¹Department of Neurosurgery, Hanyang University Guri Hospital, 153 Gyeongchun-ro,
10 Guri 471-701, Gyonggi-do, Korea, Tel.:+82.31-560-2326, Fax: +82.31-560-2327

11

12 ²Department of Neurosurgery, Hanyang University Medical Center, 222-1, Wangsimni-ro,
13 Seongdong-gu, Seoul, Korea 133-792, Tel.: +82-2-2290-8500, Fax: +82-2-2281-0954

14

15

16

17 ***Corresponding author:** Myung-Hoon Han, M.D., Ph.D.

18 Department of Neurosurgery, Hanyang University Guri Hospital, 153 Gyeongchun-ro, Guri
19 471-701, Gyonggi-do, Korea

20 Tel.: +82.31-560-2328

21 Fax: +82.31-560-2327

22 E-mail: gksmh80@gmail.com

23 ORCID ID: 0000-0003-1728-5017

24

25 **Competing Interests:** The authors have declared that no competing interests exist.

26

27 **Abstract**

28 **Background and purpose:** Disruption of the tumor-brain barrier in meningioma plays a
29 critical role in the development of peritumoral brain edema (PTBE). We hypothesized that
30 osteoporotic conditions may be associated with PTBE occurrence after radiation in patients
31 with intracranial meningioma.

32 **Methods:** We measured Hounsfield units (HU) of the frontal skull on simulation brain CT in
33 patients who underwent linear accelerator (LINAC)-based radiation treatment for intracranial
34 meningioma. Receiver operating characteristic curve analysis was performed to determine the
35 optimal cut-off values for several predictive factors. The cumulative hazard for PTBE was
36 estimated and classified according to these factors. Hazard ratios were then estimated to
37 identify independent predictive factors associated with the development of PTBE after
38 radiation in intracranial meningioma patients.

39 **Results:** A total of 83 intracranial meningiomas in 76 patients who received LINAC-based
40 radiation treatment in our hospital over an approximate 5-year period were included for the
41 study. We found mean frontal skull HU ≤ 630.625 and gross tumor volume > 7.194 cc to be
42 independent predictors of PTBE after radiation treatment in patients with meningioma (hazard
43 ratio, 8.38; $P=0.021$; hazard ratio, 5.78; $P=0.034$, respectively). In addition, patients who were
44 ≥ 65 years showed a marginally significant association with PTBE.

45 **Conclusions:** Our study suggests that possible osteoporotic conditions, large tumor volume,
46 and older age may be associated with PTBE occurrence after LINAC-based radiation
47 treatment for intracranial meningioma. In the future we anticipate that these findings may
48 enhance the understanding of the underlying mechanisms of PTBE after radiation in

49 meningioma patients.

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72 **Introduction**

73

74 Meningiomas are the most common extra-axial primary intracranial benign tumors and account
75 for 13–26% of all primary intracranial tumors [1]. Although microsurgical tumor resection is
76 the treatment of choice for symptomatic meningiomas, gross total resection of meningiomas is
77 not always possible due to various conditions such as tumor size, location, adjacent
78 neurovascular structures, or the patient’s medical status. Radiation therapy is used as a
79 treatment for meningiomas when the remnant tumor is present after surgery or when surgical
80 resection is not an option [2]. Radiotherapy for meningioma is accepted as a safe treatment
81 modality. Approximately 5% to 40% of patients experience treatment-related complications
82 [3]. It was reported that symptomatic brain edema occurs in 37.5% of patients with parasagittal
83 meningiomas after gamma knife radiosurgery [4].

84 Disruption of the tumor-brain barrier in meningioma plays a critical role in the development
85 of peritumoral brain edema (PTBE) [5]. A previous study regarding microscopic anatomy of
86 the brain–meningioma interface reported the presence of arachnoid trabeculae at the brain–
87 meningioma contact interface [6]. We previously demonstrated a close correlation between
88 bone mineral density (BMD) and Hounsfield unit (HU) values [7]. In addition, we suggested
89 that systemic osteoporosis is negatively associated with the integrity of arachnoid trabeculae
90 as both the bone and the arachnoid trabeculae are composed of type 1 collagen [7,8]. We
91 hypothesized that osteoporotic conditions may be associated with PTBE after radiation in
92 intracranial meningioma patients.

93 To test this hypothesis, we measured HU values in the frontal bone from simulation brain
94 computed tomography (CT) of patients who underwent linear accelerator (LINAC)-based

95 radiation treatment for intracranial meningioma in our hospital. We evaluated other predictive
96 risk factors for PTBE in meningioma after radiation treatment.

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114 **Methods**

115

116 **Study patients**

117 This study was approved by the Institutional Review Board of Hanyang University Medical
118 Center, Korea, and conformed to the tenets of the Declaration of Helsinki. Owing to the
119 retrospective nature of the study, the need for informed consent was waived. All patient records
120 were anonymized prior to analysis.

121 We retrospectively extracted data for all consecutive patients who were diagnosed with
122 intracranial meningioma and received LINAC-based radiation treatment for the first time from
123 the database of our hospital's NOVALIS registry, from July 7, 2014 to July 31, 2019. The
124 registry has been designed for prospective research since July 7, 2014. Demographic patient
125 information, prescribed radiation dose, and fractionation data were extracted from the
126 NOVALIS registry.

127 All intracranial meningiomas were diagnosed by radiologic findings or histological
128 confirmation following resection. All radiologic findings were confirmed by experienced
129 neuro-radiologists. We only included patients with meningioma who underwent at least one
130 follow-up imaging (CT/magnetic resonance imaging [MRI]) after LINAC-based radiation
131 treatment in order to assess the occurrence of PTBE. The last imaging follow-up period after
132 treatment was investigated in all study patients. PTBE was defined as the radiological
133 confirmation of newly developed PTBE or the progression of preexisting PTBE after radiation
134 treatment with newly developed neurological deficits. All patients had no preexisting PTBE
135 among the patients who did not undergo surgery for meningioma before radiation treatment.
136 Two patients were excluded due to no measurable cancellous bone of the frontal skull on brain

137 CT.

138

139 **Radiation technique**

140 All patients were treated using the NOVALIS Tx system (Varian Medical Systems, CA, USA;
141 Brainlab, Feldkirchen, Germany) in our hospital. A noninvasive thermoplastic mask was used
142 to perform simulation-computed tomography (CT) for radiation treatment. The Novalis
143 ExacTrac image system and robotic couch of the NOVALIS Tx system allowed us to adjust
144 the patients' positions according to the information from the real-time image acquisition.
145 Patients were treated with a 6 MV LINAC-based radiation treatment within 1 week from the
146 day when the CT simulation was performed.

147 Gross tumor volume (GTV) was defined as the contrast-enhanced area on T1-weighted MRI
148 images. In surgery patients, the GTV was defined as the postoperative resection cavity and the
149 area of residual tumor in cases of subtotal resection. The clinical target volume (CTV) was
150 identical to the GTV. The planning target volume (PTV) was defined as a symmetrical 0 to 2-
151 mm expansion from the CTV. In case the tumor was located near an organ at risk, we adjusted
152 the PTV with no expansion in the area of the tumor that was close to the organ at risk. The
153 iPlan (Brainlab, Feldkirchen, Germany) and Eclipse (Varian, CA, USA) that are 3D
154 treatment/planning systems of the NOVALIS Tx, were used for radiation planning using
155 MRI/CT-fusion images in all intracranial meningioma patients. The 3D treatment/planning
156 system automatically calculated the GTV, CTV, and PTV in all treated patients. We attempted
157 to achieve tight conformality of the treatment isodose to the 3D reconstructed meningioma
158 geometry.

159 Stereotactic radiosurgery (SRS) was defined as a single session treatment, hypofractionated

160 SRS (hf-SRS) as 2 to 5 fractions, hypofractionated stereotactic radiotherapy (hFSRT) as 6 to
161 10 fractions, and fractionated stereotactic radiotherapy (FSRT) as doses delivered in >10
162 sessions (1.8–2.0 Gy/fraction) [9,10]. The biologically equivalent dose (BED) for the tumor
163 was calculated according to the following equation: $BED = nd \times (1 + d/10)$, where n is the
164 number of fractions, d is the dose per fraction, and $\alpha/\beta=10$.

165

166 **Measurement of frontal skull HU**

167 Simulation-CT images (Philips Brilliance Big Bore CT Simulators) for radiation planning were
168 used to measure the frontal skull HU values in all study patients. A previous study reported
169 that variations in HU values across five CT scanners were in the range of 0–20 HU [11]. We
170 previously demonstrated detailed methods for measuring HU values at each of four lines on
171 the frontal cancellous bone. This was between the right and left coronal sutures on axial CT
172 slices at the point where the lateral ventricles disappear [7,12]. The HU value of the frontal
173 cancellous bone was measured using the “Linear histogram graph” function in the picture
174 archiving and communication system (PACS). The PACS automatically calculated the
175 maximum, minimum, and mean HU values according to the values on the drawn line. We
176 recorded the mean HU value on each line of cancellous bone at the frontal bone region (Fig.
177 1).

178

179 **Figure 1.** Measurement of HU values at each of four lines on the frontal bone

180 The PACS automatically calculated the maximum, minimum, and mean HU values according
181 to the values on the drawn line. The mean HU value on each of the four lines was recorded.

182 (A) Right lateral; (B) right medial; (C) left medial; (D) left lateral. HU=Hounsfield unit;

183 PACS=picture archiving and communication system.

184

185

186 To avoid including cortical bone, all brain CT images were magnified for HU measurement.

187 All frontal skull HU measurements were conducted by a trained neurosurgeon blinded to the
188 clinical data of all patients.

189

190 **Other study variables**

191 Clinical data including height, weight, hypertension, and diabetes were extracted from
192 electronic medical records. Body mass index (BMI) was calculated as weight/ (height × height)
193 and expressed in kg/m². Tumor location was confirmed by neuro-radiologists using the PACS.

194

195 **Statistical methods**

196 Continuous variables were expressed as mean ± SD or median with an interquartile range (IQR)
197 and categorical variables were expressed as counts and percentage. The chi-square test and
198 Student's t-test were used to assess statistical differences between non-PTBE and PTBE groups.
199 The mean frontal skull HU value ((mean right lateral HU + mean right medial HU + mean left
200 medial HU + mean left lateral HU)/4) was used in all analyses.

201 Receiver operating characteristic (ROC) curve analysis was performed to determine the
202 optimal cut-off values of several factors for predicting PTBE after radiation treatment in
203 meningioma patients. The optimal cut-off value was defined as the shortest distance from the
204 upper left corner. The distance between each point on the ROC curve and the upper left corner
205 was calculated as $\sqrt{(1 - \text{sensitivity})^2 + (1 - \text{specificity})^2}$ [13].

206 The cumulative hazard for PTBE was estimated using Kaplan-Meier analysis classified
207 according to several predictive factors, with censoring of patients who had no PTBE on the last
208 brain CT/MRI. Hazard ratios (HRs) with 95% confidence intervals (CIs) were then calculated
209 using univariate and multivariate Cox regression analysis. This was used to identify
210 independent predictive factors associated with the development of PTBE after LINAC-based
211 radiation treatment in intracranial meningioma patients. The *P*-values less than 0.05 were
212 considered statistically significant.

213 All statistical analyses were performed using R version 3.5.2 (<https://www.r-project.org/>).

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230 Results

231

232 Characteristics of study patients

233 Seventy-Six patients with 83 intracranial meningiomas who received LINAC-based radiation
234 treatments in our hospital over an approximate 5-year period were enrolled in the study. The
235 mean patient age was 62.8 years and 80.7% of patients were female. The median imaging
236 follow-up period was 456 days and 45.8% of patients had surgical resection before radiation
237 treatment. The mean GTV and BED were 8.4 cc and 48.8 Gy, respectively. Non-PTBE and
238 PTBE patients demonstrated significant differences in age. Details of patient characteristics are
239 presented in Table 1.

240

241

242 **Table 1.** Characteristics of patients with intracranial meningioma who underwent LINAC-
243 based radiation treatment in our hospital

| Characteristics | PTBE (-) | PTBE (+) | Total | <i>P</i> |
|--|------------------------|-------------------------|------------------------|----------|
| Number (%) | 70 (84.3) | 13 (15.7) | 83 (100) | |
| Sex, female, n (%) | 56 (80.0) | 11 (84.6) | 67 (80.7) | 1.000 |
| Age, mean \pm SD, y | 61.4 \pm 11.6 | 70.2 \pm 9.0 | 62.8 \pm 11.7 | 0.012 |
| Imaging follow-up period, median (IQR), days | 477.0 (194.8–788.0) | 435.0 (198.5–1062.5) | 456.0 (198.0–862.0) | 0.251 |
| BMI, mean \pm SD, kg/m ² | 24.7 \pm 3.7 | 24.2 \pm 3.2 | 24.6 \pm 3.6 | 0.675 |
| Height, mean \pm SD, cm | 159.1 \pm 9.4 | 155.9 \pm 7.8 | 158.6 \pm 9.2 | 0.247 |

| | | | | |
|--|-----------------|-----------------|-----------------|-------|
| Weight, mean \pm SD, kg | 62.5 \pm 11.5 | 58.5 \pm 6.7 | 61.9 \pm 10.9 | 0.228 |
| Prior surgical resection, n (%) | 35 (50.0) | 3 (23.1) | 38 (45.8) | 0.128 |
| Pathology, n (%) | | | | 0.317 |
| WHO grade I | 24 (34.3) | 2 (15.4) | 26 (31.3) | |
| WHO grade II | 8 (11.4) | 0 | 8 (9.6) | |
| WHO grade III | 3 (4.3) | 1 (7.7) | 4 (4.8) | |
| GTV, mean \pm SD, cc | 7.6 \pm 9.9 | 12.4 \pm 9.8 | 8.4 \pm 10.0 | 0.116 |
| PTV, mean \pm SD, cc | 11.7 \pm 13.7 | 17.6 \pm 11.1 | 12.7 \pm 13.4 | 0.153 |
| Location, n (%) | | | | 0.733 |
| Convexity | 22 (31.4) | 5 (38.5) | 27 (32.5) | |
| Parasagittal or parafalcine | 14 (20.0) | 4 (30.8) | 18 (21.7) | |
| Sphenoid ridge | 7 (10.0) | 1 (7.7) | 8 (9.6) | |
| Cerebellopontine angle | 7 (10.0) | 2 (15.4) | 9 (10.8) | |
| Posterior fossa | 7 (10.0) | 1 (7.7) | 8 (9.6) | |
| Parasellar or petroclival | 10 (14.3) | 0 | 10 (12.0) | |
| Other | 3 (4.3) | 0 | 3 (3.6) | |
| Marginal radiation dose, mean \pm SD, Gy | 31.5 \pm 12.0 | 26.7 \pm 5.6 | 30.8 \pm 11.4 | 0.161 |
| Fractionation, n (%) | | | | 0.372 |
| SRS | 13 (18.6) | 3 (23.1) | 16 (19.3) | |
| hf-SRS (2-5 fractions) | 39 (55.7) | 9 (69.2) | 48 (57.8) | |

| | | | | |
|--|------------------|------------------|------------------|-------|
| hFSRT (6-10 fractions) | 4 (5.7) | 1 (7.7) | 5 (6.0) | |
| FSRT | 14 (20.0) | 0 | 14 (16.9) | |
| Dose per fraction median (IQR), Gy | 5.8 (4.8–7.0) | 6.0 (5.4–11.3) | 5.8 (5.3–7.0) | 0.418 |
| BED ($\alpha/\beta = 10$), mean \pm SD, Gy | 49.2 \pm 8.7 | 46.4 \pm 4.7 | 48.8 \pm 8.2 | 0.264 |
| BED ($\alpha/\beta = 10$), median (IQR), Gy | 46.8 (44.5–52.7) | 45.8 (41.6–49.2) | 45.9 (43.7–51.2) | 0.264 |
| Past medical history, n (%) | | | | |
| Hypertension | 29 (41.4) | 6 (46.2) | 35 (42.2) | 0.768 |
| Diabetes | 13 (18.6) | 3 (23.1) | 16 (19.3) | 0.708 |

244 LINAC, linear accelerator; PTBE, peritumoral brain edema; SD, standard deviation; IQR,
 245 interquartile range; BMI, body mass index; WHO, world health organization; GTV, gross
 246 tumor volume; PTV, planning target volume; SRS, stereotactic radiosurgery; hf-SRS,
 247 hypofractionated stereotactic radiosurgery; hFSRT, hypofractionated stereotactic radiotherapy;
 248 FSRT, fractionated stereotactic radiotherapy; BED, biologically equivalent dose

249

250

251 **Mean frontal skull HU values, according to PTBE in study patients**

252 Table 2 shows descriptive statistics of frontal skull HU values according to PTBE after
 253 radiation treatment.

254

255

256 **Table 2.** Descriptive statistics of the mean frontal skull HU values according to peritumoral

257 brain edema after LINAC-based radiation treatment in patients with intracranial meningi
 258 oma

| Characteristics | PTBE (-) | PTBE (+) | Total | <i>P</i> |
|---|------------------------|------------------------|------------------------|----------|
| Overall mean frontal skull HU value, median (IQR) | 733.6 (559.3–870.1) | 547.8 (415.6–677.5) | 725.8 (527.0–853.3) | 0.018 |
| Overall mean frontal skull HU value, mean ± SD | 735.4 ± 246.2 | 564.4 ± 161.7 | 708.6 ± 242.4 | 0.018 |
| Mean HU value at each of four sites in the frontal skull, mean ± SD | | | | |
| Right lateral | 707.3 ± 245.1 | 579.2 ± 124.9 | 687.2 ± 234.6 | 0.070 |
| Right medial | 773.6 ± 268.7 | 588.9 ± 191.3 | 744.7 ± 265.9 | 0.021 |
| Left medial | 738.8 ± 271.4 | 566.2 ± 201.9 | 711.8 ± 268.2 | 0.032 |
| Left lateral | 722.1 ± 259.0 | 523.2 ± 166.3 | 690.9 ± 256.5 | 0.009 |
| Average, medial | 756.2 ± 266.0 | 577.5 ± 190.6 | 728.2 ± 262.9 | 0.024 |
| Average, lateral | 714.7 ± 247.9 | 551.2 ± 143.3 | 689.1 ± 241.4 | 0.024 |
| Classification of skull HU, n (%) | | | | 0.005 |
| Mean frontal skull HU ≤630.6 | 23 (32.9) | 10 (76.9) | 33 (39.8) | |
| Mean frontal skull HU >630.6 | 47 (67.1) | 3 (23.1) | 50 (60.2) | |

259 HU, Hounsfield unit; LINAC, linear accelerator; PTBE, peritumoral brain edema; IQR,

260 interquartile range; SD, standard deviation

261

262

263 We observed significant differences in values of the mean frontal skull HU and classification
264 of the skull HU between non-PTBE and PTBE groups. The overall average mean frontal skull
265 HU value was 725.8 in all study patients, 733.6 in the non-PTBE group and 547.8 in the PTBE
266 group.

267

268 **Determination of the optimal cut-off values of predictive factors for** 269 **PTBE after radiation**

270 The optimal cut-off values of age, mean frontal skull HU, and GTV for the prediction of PTBE
271 in patients with intracranial meningioma after radiation were 65 years (area under the curve
272 [AUC]=0.730; sensitivity=84.6%; specificity=65.7%; $P=0.009$), 630.625 (AUC=0.716;
273 sensitivity=76.9%; specificity=67.1%; $P=0.014$), and 7.194 cc (AUC=0.706;
274 sensitivity=69.2%; specificity=71.4%; $P=0.019$), respectively (Fig. 2A–C).

275

276

277 **Figure 2.** Comparisons of age mean frontal skull HU value, GTV, and BED between PTBE
278 and non-PTBE groups This includes the determination of the optimal cut-off values of the
279 predictive factors for PTBE occurrence after radiation in intracranial meningioma. (A)
280 Boxplots with dot plots of age according to the PTBE and ROC curve to identify the optimal
281 cutoff value of age for the prediction of PTBE; (B) Boxplots with dot plots of mean frontal
282 skull HU according to the PTBE and ROC curve to identify the optimal cutoff value of mean
283 frontal skull HU for the prediction of PTBE; (C) Boxplots with dot plots of GTV according to
284 the PTBE and ROC curve to identify the optimal cutoff value of GTV for the prediction of
285 PTBE; (D) Boxplots with dot plots of BED according to the PTBE and ROC curve to identify

286 the optimal cutoff value of BED for the prediction of PTBE. PTBE=peritumoral brain edema;
287 AUC=area under the curve; HU=Hounsfield unit; GTV=gross tumor volume; BED=
288 biologically equivalent dose; ROC=receiver operating characteristic.

289

290

291 However, BED did not show statistical significance in the ROC analysis ($P=0.335$), (Fig. 2D).

292 According to the cut-off values, the study patients were classified into (1) ≥ 65 years (2) mean
293 frontal skull HU ≤ 630.625 , and (3) GTV > 7.194 cc groups.

294

295 **Cumulative hazard of PTBE after radiation according to several** 296 **predictive factors**

297 The incidence of PTBE was significantly higher among patients who were ≥ 65 years, with a
298 mean frontal skull HU ≤ 630.625 , and a GTV > 7.194 cc in the clinical course of intracranial
299 meningioma after LINAC-based radiation treatment (Fig. 3A–C).

300

301

302 **Figure 3.** Cumulative hazard of PTBE after LINAC-based radiation treatment for intracranial
303 meningioma according to the several predictive factors

304 (A) age group (cut-off value of 65); (B) mean frontal skull HU (cut-off value of 630.625); (C)

305 GTV (cut-off value of 7.194); (D) two fractionation categories (SRS or hf-SRS versus hFSRT

306 or FSRT). PTBE=peritumoral brain edema; HU=Hounsfield unit; GTV=gross tumor volume;

307 SRS=stereotactic radiosurgery; hf-SRS= hypofractionated stereotactic radiosurgery; hFSRT=

308 hypofractionated stereotactic radiotherapy; FSRT= fractionated stereotactic radiotherapy.

309

310

311 Patients with ≤ 5 fractionation (SRS or hf-SRS) also tended to have higher rates of PTBE after
312 radiation (Fig. 3D, $P=0.159$).

313

314 **Independent predictive factors for PTBE after radiation in** 315 **meningioma patients**

316 The multivariate Cox regression analysis identified a mean frontal skull HU ≤ 630.625 and
317 GTV > 7.194 cc as independent predictors of PTBE after LINAC-based radiation treatment in
318 intracranial meningioma patients (HR, 8.38; 95% CI, 1.38–50.73; $P=0.021$; HR, 5.78; 95% CI,
319 1.14–29.39; $P=0.034$, respectively); (Table 3).

320

321

322 **Table 3.** Univariate and multivariate Cox regression analyses for the development of
323 peritumoral brain edema in patients with intracranial meningioma after LINAC-based radiation
324 treatment based on predictive variables

| Variable | Univariate analysis | | Multivariate analysis | |
|-----------------|---------------------|----------|-----------------------|----------|
| | HR (95% CI) | <i>P</i> | HR (95% CI) | <i>P</i> |
| Sex | | | | |
| Male | Reference | | Reference | |
| Female | 1.27 (0.28–5.80) | 0.759 | 0.83 (0.16–4.16) | 0.818 |
| Age group | | | | |
| <65 years | Reference | | Reference | |
| ≥ 65 years | 11.24 (2.47–51.27) | 0.002 | 5.20 (1.00–27.13) | 0.050 |

| | | | | |
|--|-------------------|-------|-------------------|-------|
| BMI (per 1 BMI increase) | 0.95 (0.80–1.14) | 0.610 | 0.98 (0.77–1.26) | 0.893 |
| Mean frontal skull HU | | | | |
| ≤630.6 | 9.83 (2.13–45.23) | 0.003 | 8.38 (1.38–50.73) | 0.021 |
| >630.6 | Reference | | Reference | |
| GTV | | | | |
| ≤7.2 cc | Reference | | Reference | |
| >7.2 cc | 4.17 (1.27–13.74) | 0.019 | 5.78 (1.14–29.39) | 0.034 |
| Location | | | | |
| Convexity | 2.41 (0.74–7.88) | 0.145 | 1.96 (0.53–7.23) | 0.310 |
| Other regions | Reference | | Reference | |
| BED ($\alpha/\beta=10$) (per 1 Gy increase) | 0.96 (0.89–1.04) | 0.352 | 0.97 (0.85–1.11) | 0.688 |
| Fractionation (per 1 fraction increase) | 0.92 (0.82–1.04) | 0.184 | 0.77 (0.49–1.20) | 0.240 |

325 HR, hazard ratio; CI, confidence interval; BMI, body mass index; HU, Hounsfield unit; GTV,
326 gross tumor volume; BED, biologically equivalent dose

327

328

329 Patients who were ≥ 65 years showed a marginal statistically significant association with PTBE
330 occurrence after full adjustment (HR, 5.20; 95% CI, 1.00–27.13; $P=0.050$).

331 Although we adjusted the age group in the multivariate analysis, a negative relationship
332 between age and BMD may affect our results. We also identified a close association between
333 age and mean frontal skull HU values in the study patients in S1 Fig. We further performed
334 additional multivariate Cox regression with the adjustment for age as a continuous variable in
335 the S1 Table. The results showed that the mean frontal skull HU ≤ 630.625 was maintained as
336 an independent predictor of PTBE (HR, 6.99; 95% CI, 1.12–43.60; $P=0.037$). When we

337 adjusted for the past medical history, mean frontal skull HU ≤ 630.625 showed a strong
338 association with PTBE in the study patients (S2 Table).

339 When the patients were divided into the risk factor group (age ≥ 65 years and skull HU
340 ≤ 630.625 and GTV > 7.194 cc) and others, the rate of PTBE was significantly higher in the risk
341 factor group than in the others (Fig. 4). The univariate Cox analysis showed a strong significant
342 association between PTBE and the risk factor group (HR, 21.92; 95% CI, 6.10 to 78.74;
343 $P < 0.001$).

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

362 **Discussion**

363

364 We found that PTBE was independently associated with possible low BMD and large tumor
365 volume in the clinical course of intracranial meningioma after LINAC-based radiation
366 treatment. Older age showed a marginal independent association with PTBE occurrence after
367 radiation. The possible low BMD group (mean skull HU ≤ 630.6) had an approximate 7.0 to
368 9.0-fold increased risk of PTBE after adjusting for other predictive factors including age. To
369 our knowledge, this study is the first to suggest that BMD is associated with PTBE after
370 radiation treatment in patients with intracranial meningioma.

371 It is well accepted that the tumor-brain barrier disruption may be an essential component of
372 PTBE formation [5]. Glioblastoma and metastatic tumors usually induce PTBE. However, in
373 contrast to glioblastomas and metastases, meningiomas are encapsulated and are separated
374 from the underlying normal cerebral cortex by the arachnoid membrane and pia mater. The
375 arachnoid membrane is impermeable to fluids due to its' tight intercellular junctions [14]. It is
376 thought that the arachnoid membrane may act as a mechanical and biochemical buffer against
377 mediators released from a meningioma [15]. It is probable that the arachnoid membrane blocks
378 the spread of edema-associated proteins such as endothelial growth factor/vascular
379 permeability factor and vasogenic edema fluids from meningiomas from the peritumoral brain
380 tissue [3]. A previous study that examined the microscopic anatomy of the brain-meningioma
381 interface, also reported that the degree of arachnoid disruption correlated with the presence of
382 perifocal edema [6].

383 Interestingly, a microscopic examination of the brain-meningioma interface revealed
384 proliferation of hyperplastic arachnoid trabeculae, (below the arachnoid membrane at the

385 brain–meningioma interface) in the meningioma with a thin connective capsule (shown in Fig.
386 1A of the study) [6]. After the study, it was reported that the arachnoid trabeculae and
387 granulations are composed of type 1 collagen [16]. The arachnoid is composed of two layers.
388 An outer part of the arachnoid is the arachnoid barrier layer and is an actual membrane cover.
389 An inner part is the arachnoid trabeculae maintaining the stability of the subarachnoid space
390 and cerebrospinal fluid flow to support the arachnoid barrier layer [17]. Arachnoid cap cells
391 are believed to be of meningioma cell origin [18]. Therefore, it is possible to postulate that
392 meningioma from arachnoid cap cells may naturally push the arachnoid trabeculae into the pia
393 mater [19]. As the tumor grows, it could also be assumed that arachnoid trabeculae may be
394 sandwiched between the pia mater and meningioma. This may form part of the tumor-brain
395 contact interface. Compression due to the growth of a tumor on adjacent venous structures,
396 leptomeninges, and the cerebral cortex may lead to an increase in hydrostatic pressure [20].

397 It is well documented that type 1 collagen is a major component of bone. Osteoporosis is a
398 systemic disease that affects systemic bone mass and microarchitecture throughout the body.
399 We previously reported the close association between mean frontal skull HU and BMD [7,12].
400 We also demonstrated that systemic osteoporosis may negatively affect the integrity of
401 arachnoid trabeculae and granulations because bone, arachnoid trabeculae, and granulations
402 are all composed of type 1 collagen [7,8]. Supporting our hypothesis, osteogenesis imperfecta,
403 that is caused by mutations in type 1 procollagen genes (*COL1A1/COL1A2*), is associated with
404 communicating hydrocephalus [21]. We believe that trabeculae, which are sandwiched
405 between the pia mater and meningioma, may be more impaired and weakened in osteoporotic
406 patients when compared to healthy patients.

407 Previous studies described that irradiation affects collagen structure and can lead to collagen
408 changes and damage [22,23]. When the meningioma is not treated with surgery or radiation

409 therapy, tumor growth is the primary cause of damage to the tumor-brain contact interface
410 including the arachnoid trabeculae. After radiation, this contact interface may be damaged by
411 radiation activities [3].

412 Based on the above findings and assumptions, we propose the following hypothetical
413 mechanism as an explanation for the association between possible low BMD, large tumor
414 volume, and PTBE after radiation for intracranial meningioma. As tumor grows, the tumor may
415 push more of the arachnoid trabeculae into the pia mater and cause damage to the tumor-brain
416 contact interface. The larger the tumor, the greater the likelihood of damage to the tumor-brain
417 contact interface including the arachnoid trabeculae. The damage to the arachnoid trabeculae
418 due to compression by the tumor will be more severe in osteoporotic patients. Radiation may
419 aggravate the damaged tumor-brain contact interface including the arachnoid trabeculae and
420 may lead to tumor-brain barrier disruption. We hypothesized that the more damaged the
421 arachnoid trabeculae are at the tumor-brain interface due to low BMD and large tumor volume,
422 the higher the possibility will be of tumor-brain barrier disruption after radiation therapy.
423 Tumor-brain barrier disruption may result in PTBE formation in meningioma patients after
424 radiation.

425 Loosening of the microstructure network and the volume reduction of aging white matter
426 may increase the possibility of PTBE. This allows direct transmission of edematous fluids into
427 the white matter [24]. We believe that thorough precautions are required with older patients
428 with osteoporosis and large tumor volume, after radiation therapy for intracranial meningioma.
429 We also found that BED was not associated with PTBE occurrence in our study. We propose
430 that this was because we did not use extremely high radiation doses and the narrow BED range
431 may not have resulted in significant differences in PTBE occurrence [3]. We believe that the
432 status of the brain-meningioma contact interface, including the arachnoid trabeculae, is a more

433 important factor than the radiation dosage in predicting PTBE occurrence after radiation for
434 meningioma. Although it falls short of significance, multi-fraction seems to be important for
435 prevention of PTBE after radiation for meningioma.

436 Our study has several limitations. First, due to the retrospective nature of the study, the
437 length of follow-ups and the number of follow-up images varied widely. Second, HU
438 measurement errors may have occurred. However, all brain CT images were magnified for HU
439 measurement to reduce errors. We excluded patients with no measurable cancellous bone of
440 the frontal skull in the simulation brain CT. To reduce measurement errors, we estimated mean
441 HU values in four areas of the frontal skull and averaged them. Third, although HU values are
442 correlated with BMD, HU values may not reflect the exact BMD values. Fourth, heterogeneity
443 in tumor location and absence of histological confirmation in many cases may affect the results
444 of the study. Lastly, the small number of cases may have reduced the statistical power and
445 validation.

446 In conclusion, our study suggests that possible osteoporotic conditions, large tumor volume,
447 and older age may be associated with PTBE occurrence after LINAC-based radiation treatment
448 for intracranial meningioma. We believe that these findings may be helpful for predicting
449 PTBE occurrence during the clinical course of meningioma after radiation. In the future, we
450 anticipate that the findings of this study may enhance the understanding of the underlying
451 mechanisms of PTBE after radiation in meningioma patients.

452

453

454

455

456

457

458 **Author Contributions:**

459 Dr M.H.H had full access to all data in the study and takes responsibility for the integrity of
460 the data and the accuracy of the data analysis. All authors reviewed the manuscript.

461

462 Ryang-Hun Lee-

463 Data curation

464 Investigation

465 Writing – original draft

466

467 Jae Min Kim-

468 Supervision

469

470 Jin Hwan Cheong-

471 Supervision

472 Resources

473

474 Je Il Ryu-

475 Supervision

476 Writing – review & editing

477

478 Young Soo Kim-

479 Supervision

480

481 Myung-Hoon Han-

482 Conceptualization

483 Methodology

484 Formal Analysis

485 Visualization

486 Writing – original draft

487

488

489

490

491

492

493

494

495

496

497

498

499 **Acknowledgments:** This study was funded by Basic Science Research Program
500 through the National Research Foundation of Korea (NRF) funded by the Ministry of Science,
501 ICT & Future Planning (NRF-2019R1G1A1085289).

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534 **References**

535

- 536 1. Whittle IR, Smith C, Navoo P, Collie D. Meningiomas. *The Lancet*. 2004;363: 1535–
537 1543. doi:10.1016/S0140-6736(04)16153-9
- 538 2. Pinzi V, Bisogno I, Prada F, Ciusani E, Fariselli L. Radiotherapy of meningioma: a
539 treatment in need of radiobiological research. *International Journal of Radiation Biology*.
540 2018;94: 621–627. doi:10.1080/09553002.2018.1478157
- 541 3. Cai R, Barnett GH, Novak E, Chao ST, Suh JH. Principal risk of peritumoral edema after
542 stereotactic radiosurgery for intracranial meningioma is tumor-brain contact interface area.
543 *Neurosurgery*. 2010;66: 513–522. doi:10.1227/01.NEU.0000365366.53337.88
- 544 4. Singh VP, Kansai S, Vaishya S, Julka PK, Mehta VS. Early complications following
545 gamma knife radiosurgery for intracranial meningiomas. *J Neurosurg*. 2000;93 Suppl 3:
546 57–61. doi:10.3171/jns.2000.93.supplement
- 547 5. Hou J, Kshetry VR, Selman WR, Bambakidis NC. Peritumoral brain edema in
548 intracranial meningiomas: the emergence of vascular endothelial growth factor-directed
549 therapy. *Neurosurg Focus*. 2013;35: E2. doi:10.3171/2013.8.FOCUS13301
- 550 6. Nakasu S, Fukami T, Jito J, Matsuda M. Microscopic anatomy of the brain-meningioma
551 interface. *Brain Tumor Pathol*. 2005;22: 53–57. doi:10.1007/s10014-005-0187-0
- 552 7. Han M-H, Won YD, Na MK, Kim CH, Kim JM, Ryu JI, et al. Association Between
553 Possible Osteoporosis and Shunt-Dependent Hydrocephalus After Subarachnoid

- 554 Hemorrhage. *Stroke*. 2018;49: 1850–1858. doi:10.1161/STROKEAHA.118.021063
- 555 8. Bae I-S, Kim JM, Cheong JH, Ryu JI, Han M-H. Association between bone mineral
556 density and brain parenchymal atrophy and ventricular enlargement in healthy individuals.
557 *Aging (Albany NY)*. 2019;11: 8217–8238. doi:10.18632/aging.102316
- 558 9. Meniai-Merzouki F, Bernier-Chastagner V, Geffrelot J, Tresch E, Lacornerie T, Coche-
559 Dequeant B, et al. Hypofractionated Stereotactic Radiotherapy for Patients with
560 Intracranial Meningiomas: impact of radiotherapy regimen on local control. *Sci Rep*.
561 2018;8: 13666. doi:10.1038/s41598-018-32124-8
- 562 10. Kirkpatrick JP, Soltys SG, Lo SS, Beal K, Shrieve DC, Brown PD. The radiosurgery
563 fractionation quandary: single fraction or hypofractionation? *Neuro-oncology*. 2017;19:
564 ii38–ii49. doi:10.1093/neuonc/now301
- 565 11. Birnbaum BA, Hindman N, Lee J, Babb JS. Multi-detector row CT attenuation
566 measurements: assessment of intra- and interscanner variability with an anthropomorphic
567 body CT phantom. *Radiology*. 2007;242: 109–119. doi:10.1148/radiol.2421052066
- 568 12. Na MK, Won YD, Kim CH, Kim JM, Cheong JH, Ryu JI, et al. Opportunistic osteoporosis
569 screening via the measurement of frontal skull Hounsfield units derived from brain
570 computed tomography images. *PLoS ONE*. 2018;13: e0197336.
571 doi:10.1371/journal.pone.0197336
- 572 13. Tuan NT, Adair LS, He K, Popkin BM. Optimal cutoff values for overweight: using body
573 mass index to predict incidence of hypertension in 18–65-year-old Chinese adults. *J Nutr*.
574 2008;138: 1377–1382.

- 575 14. Weller RO. Microscopic morphology and histology of the human meninges. *Morphologie*.
576 2005;89: 22–34.
- 577 15. Conti A, Pontoriero A, Siddi F, Iati G, Cardali S, Angileri FF, et al. Post-Treatment Edema
578 after Meningioma Radiosurgery is a Predictable Complication. *Cureus*. 8.
579 doi:10.7759/cureus.605
- 580 16. Saboori P, Sadegh A. Histology and Morphology of the Brain Subarachnoid Trabeculae.
581 *Anat Res Int*. 2015;2015: 279814. doi:10.1155/2015/279814
- 582 17. Yamashima T. Human Meninges: Anatomy and Its Role in Meningioma Pathogenesis.
583 In: Lee JH, editor. *Meningiomas*. London: Springer; 2009. pp. 15–24. doi:10.1007/978-
584 1-84628-784-8_3
- 585 18. Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. *J*
586 *Neurooncol*. 2010;99: 307–314. doi:10.1007/s11060-010-0386-3
- 587 19. arachnoid_cap_cell [Operative Neurosurgery]. [cited 25 Oct 2019]. Available:
588 https://operativeneurosurgery.com/doku.php?id=arachnoid_cap_cell
- 589 20. Hanna A, Boggs DH, Kwok Y, Simard M, Regine WF, Mehta M. What predicts early
590 volumetric edema increase following stereotactic radiosurgery for brain metastases? *J*
591 *Neurooncol*. 2016;127: 303–311. doi:10.1007/s11060-015-2034-4
- 592 21. Charnas LR, Marini JC. Communicating hydrocephalus, basilar invagination, and other
593 neurologic features in osteogenesis imperfecta. *Neurology*. 1993;43: 2603–2608.
594 doi:10.1212/wnl.43.12.2603

595 22. Miller JP, Borde BH, Bordeleau F, Zanotelli MR, LaValley DJ, Parker DJ, et al. Clinical
596 doses of radiation reduce collagen matrix stiffness. *APL Bioengineering*. 2018;2: 031901.
597 doi:10.1063/1.5018327

598 23. Maslennikova A, Kochueva M, Ignatieva N, Vitkin A, Zakharkina O, Kamensky V, et al.
599 Effects of gamma irradiation on collagen damage and remodeling. *Int J Radiat Biol*.
600 2015;91: 240–247. doi:10.3109/09553002.2014.969848

601 24. Gunning-Dixon FM, Brickman AM, Cheng JC, Alexopoulos GS. Aging of cerebral white
602 matter: a review of MRI findings. *Int J Geriatr Psychiatry*. 2009;24: 109–117.
603 doi:10.1002/gps.2087

604

605

606

607

608

609

610

611

612

613 **Supporting Information**

614

615 **S1 Figure.** Scatterplot with linear regression line showing the association between age and
616 mean frontal skull HU values. HU=Hounsfield unit.

617

618 **S1 Table.** Uni- and multivariate Cox regression analyses for the development of peritumoral
619 brain edema in patients with intracranial meningioma after LINAC-based radiation treatment
620 based on predictive variables (adjusted for age as continuous variable).

621

622 **S2 Table.** Uni- and multivariate Cox regression analyses for the development of peritumoral
623 brain edema in patients with intracranial meningioma after LINAC-based radiation treatment
624 based on predictive variables (adjusted for age as continuous variable and past medical history).

625

626









Figure 1



bioRxiv preprint doi: <https://doi.org/10.1101/856211>; this version posted November 26, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.









Figure2








Figure3

+ Others
 + Risk factor group (age ≥ 65 years and skull HU ≤ 630.625 and GTV > 7.194 cc)



Number at risk

| Days | 0 | 100 | 200 | 300 | 400 | 500 | 600 | 700 | 800 | 900 | 1000 | 1100 | 1200 | 1300 | 1400 | 1500 |
|-------------------------|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|------|------|------|------|------|
| Others (Blue) | 73 | 65 | 54 | 45 | 41 | 35 | 26 | 22 | 19 | 13 | 6 | 5 | 5 | 4 | 2 | 1 |
| Risk factor group (Red) | 10 | 8 | 5 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

Cumulative number of events

| Days | 0 | 100 | 200 | 300 | 400 | 500 | 600 | 700 | 800 | 900 | 1000 | 1100 | 1200 | 1300 | 1400 | 1500 |
|-------------------------|---|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|------|------|------|------|------|
| Others (Blue) | 0 | 2 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 6 | 6 | 6 |
| Risk factor group (Red) | 0 | 2 | 3 | 6 | 6 | 6 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 |

Figure4